Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) – Equities researchers at Wedbush boosted their FY2019 earnings estimates for Catabasis Pharmaceuticls in a research report issued to clients and investors on Tuesday. Wedbush analyst L. Moussatos now forecasts that the brokerage will post earnings of ($2.65) per share for the year, up from their previous estimate of ($2.83). Wedbush has a “Outperform” rating and a $17.00 price objective on the stock.

Catabasis Pharmaceuticls (NASDAQ:CATB) last released its quarterly earnings data on Thursday, August 11th. The company reported ($0.61) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.04.

Earnings History and Estimates for Catabasis Pharmaceuticls (NASDAQ:CATB)

Several other equities research analysts also recently commented on CATB. Cowen and Company reiterated a “buy” rating on shares of Catabasis Pharmaceuticls in a research note on Wednesday, June 8th. Zacks Investment Research upgraded shares of Catabasis Pharmaceuticls from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a research note on Tuesday, July 5th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $19.05.

Catabasis Pharmaceuticls (NASDAQ:CATB) traded up 0.18% on Thursday, hitting $5.44. 223,049 shares of the company’s stock traded hands. The stock’s market cap is $83.67 million. Catabasis Pharmaceuticls has a one year low of $3.31 and a one year high of $10.83. The stock has a 50-day moving average of $4.76 and a 200-day moving average of $4.76.

A hedge fund recently raised its stake in Catabasis Pharmaceuticls stock. Sphera Funds Management LTD. raised its stake in Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) by 184.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 230,041 shares of the company’s stock after buying an additional 149,299 shares during the period. Sphera Funds Management LTD. owned 1.50% of Catabasis Pharmaceuticls worth $1,159,000 at the end of the most recent reporting period. Institutional investors own 57.27% of the company’s stock.

About Catabasis Pharmaceuticls

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

5 Day Chart for NASDAQ:CATB

Receive News & Stock Ratings for Catabasis Pharmaceuticls Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticls Inc. and related stocks with our FREE daily email newsletter.